Taysha Gene Therapies, Inc.

TSHA

$5.57

-1.24%

N/A-$0.07

Healthcare

Biotechnology

NASDAQ

Active Trading

Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus ...

Financial Highlights of TSHA

Profitability trend

Latest / TTM · 6 periods

Gross Margin

84.0%

Net Margin

-2728.0%

P/E Ratio

-13.18x

n/a

Debt / Equity

0.14

n/a

Current Ratio

17.76

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Financial highlights

Latest / TTM · 6 periods

Snapshot

Latest / TTM: 2026-09-04

Gross Margin

84.0%

Net Margin

-2728.0%

P/E Ratio

-13.18x

Debt / Equity

0.14

Profitability

Profitability table

Metric	2021	2022	2023	2024	2025	2026
Gross MarginGross profit as a percentage of revenue.	0.0%	0.6%	100.0%	100.0%	100.0%	—
Operating MarginOperating income as a percentage of revenue.	0.0%	-5037.1%	-468.8%	-1097.6%	-1130.6%	—
Net MarginNet income as a percentage of revenue.	0.0%	-6635.3%	-722.1%	-1071.6%	-1115.3%	—
EBITDA MarginEBITDA divided by revenue.	0.0%	-6384.1%	-680.8%	-1055.5%	-1102.9%	—
Pre-tax MarginPre-tax profit as a percentage of revenue.	0.0%	-6635.3%	-722.1%	-1071.6%	-1115.3%	—

Liquidity & leverage

Liquidity & leverage table

Metric	2021	2022	2023	2024	2025	2026
Current RatioCurrent assets divided by current liabilities.	3.08	1.54	4.08	5.42	12.23	—
Quick RatioLiquid assets divided by current liabilities.	3.08	1.54	4.08	5.42	12.23	—
Cash RatioCash and equivalents divided by current liabilities.	2.88	1.40	3.92	5.30	12.04	—
Debt / AssetsDebt as a share of total assets.	29.5%	47.5%	35.4%	39.4%	5.3%	—
Debt / EquityDebt compared with shareholder equity.	0.66	63.15	0.82	0.88	0.07	—

Operating efficiency

Operating efficiency table

Metric	2021	2022	2023	2024	2025	2026
Receivables TurnoverHow often receivables are collected in a year.	0.00x	0.00x	0.00x	0.00x	0.00x	—
Inventory TurnoverHow often inventory is sold in a year.	0.00x	0.00x	0.00x	0.00x	0.00x	—
Payables TurnoverHow often payables are paid in a year.	0.00x	0.23x	0.00x	0.00x	0.00x	—
Asset TurnoverRevenue generated per dollar of assets.	0.00x	0.02x	0.09x	0.05x	0.03x	—
Working Capital TurnoverRevenue generated per dollar of working capital.	0.00x	0.04x	0.21x	0.07x	0.05x	—

Valuation ratios

Valuation ratios table

Metric	2021	2022	2023	2024	2025	2026
P/E RatioPrice paid for each dollar of earnings.	-2.51x	-0.60x	-1.84x	-4.81x	-16.18x	—
P/B RatioPrice paid for each dollar of book value.	4.60x	104.67x	2.74x	6.05x	7.12x	—
P/S RatioPrice paid for each dollar of sales.	0.00x	39.70x	13.30x	51.93x	179.93x	—
P/FCF RatioPrice paid for each dollar of free cash flow.	-3.16x	-0.88x	-2.56x	-5.30x	-18.74x	—
Dividend YieldAnnual dividend divided by current share price.	0.0%	0.0%	0.0%	0.0%	0.0%	—

Upstream

Catalent, Inc. (now Novo Holdings)The University of Texas Southwestern Medical Center (UTSW)Abeona Therapeutics Inc.NASDAQ:ABEOTaysha Gene Therapies — Durham Internal Manufacturing FacilityUniversity of North Carolina at Chapel Hill (UNC)Cleveland ClinicYale UniversityAldevron (subsidiary of Danaher Corporation)NYSE:DHR Thermo Fisher Scientific Inc.NYSE:TMOLonza Group AGSWX:LONN

Downstream

Astellas Pharma Inc. (former strategic partner)TYO:4503AllStripes (now part of Ciitizen / RDMD)Clinical Trial Sites (Hospitals & Research Centers)

Proxies

Neurogene Inc.NASDAQ:NGNE REGENXBIO Inc.NASDAQ:RGNX Voyager Therapeutics, Inc.NASDAQ:VYGR Abeona Therapeutics Inc.NASDAQ:ABEOCatalent, Inc. (pre-acquisition)Unconfirmed

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

No matching stocks found

Taysha Gene Therapies, Inc.

Financial Highlights of TSHA

Financial highlights

Snapshot

Profitability

Liquidity & leverage

Operating efficiency

Valuation ratios

Supply Chain of TSHA

Upstream

Downstream

Proxies

Financial Highlights of TSHA

Financial highlights

Snapshot

Profitability

Liquidity & leverage

Operating efficiency

Valuation ratios

Supply Chain of TSHA

Upstream

Downstream

Proxies